As human hair wigs look just like natural hair, is it prone to similar issues as natural hair, and wigs harboring lice is one of them.
Appropriate Standard Thirty seven carries a free-sprung stability with fake richard mille out regulator, including Patek Philippe’s Gyromax, and the rate is adjusted by simply Four weight screws (within platinum) on the harmony edge.
BayPAT | TMEM16A inhibitors as a treatment option for polycystic… Zum Seiteninhalt springen
Back to overview

21.10.2020

TMEM16A inhibitors as a treatment option for polycystic kidney disease (PKD)

Life Sciences, Kardiovaskuläre Erkrankung

  • TMEM16A inhibitors represent a causative treatment for polycystic kidney disease
  • Significant suppression of renal cysts
  • Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs

Ihr Kontakt

Dr. Katrin Bercht

E-Mail:
kbercht@baypat.de
Telefon:
+49 (0) 89 5480177 - 16
Referenznummer:
B79076

Herausforderung

Polycystic Kidney Disease (PKD) comprises a group of inherited disorders that lead to multiple fluid-filled renal cysts. The most common form, autosomal dominant PKD (ADPKD), affects 1 in 1000 people, and accounts for 10% of end-stage renal disease, which often necessitates long term treatment, dialysis and/or kidney transplantation.

Innovation

The Ca2+-regulated chloride ion channel TMEM16A is central to ADPKD. Inhibition of TMEM16A by inhibitors such as the FDA-approved and well-tolerated drugs niclosamide and benzbromarone largely suppress cyst development, as demonstrated in preclinical studies in-vivo. A large number of patients would be likely to benefit from this novel therapeutic concept for the treatment of ADPKD. It could strongly reduce the costs for public health care and lower the patient’s burden caused by invasive medical treatments.

Kommerzielle Möglichkeiten

  • TMEM16A inhibitors include FDA approved and well-tolerated drugs such as niclosamide and benzbromarone
  • TMEM16A inhibitors represent a causative treatment for ADPKD
  • Significant suppression of renal cysts

Entwicklungsstatus

Efficacy shown in-vivo. Currently seeking partners for further development and licensing.

References

  • 1

    Cabrita I et al. “Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in-vivo”. Nat Commun. 2020 Aug 28;11(1):4320.

Haben wir Ihr Interesse geweckt?

Finden Sie den richtigen Ansprechpartner für spezielle Themen auf unserer Team-Seite oder benutzen Sie für Ihre Anfrage einfach das Kontakt-Formular.